In 2023, the treatment success rate for patients treated for multidrug-resistant tuberculosis in Germany stood at approximately 51%. The forecast for 2024 to 2028 indicates a gradual but modest increase, mostly plateauing at a 53% success rate by 2026. This represents a consistent, albeit slow, positive change, with a Compound Annual Growth Rate (CAGR) of around 0.77% over this period. Given the stability in the figures, the year-on-year variation between 2023 to 2028 remains minimal.
Future trends to watch for include:
- Emergence of new treatment protocols aimed at enhancing effectiveness.
- Potential impact of technological advancements in diagnostics and personalized medicine.
- Policy changes and healthcare funding could alter dynamics significantly.
- Global initiatives to combat TB which might improve treatment rates.
